Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer.

He X, Ji J, Tian M, Esteva FJ, Hortobagyi GN, Yeung SJ.

Clin Cancer Res. 2019 Sep 12. pii: clincanres.0463.2019. doi: 10.1158/1078-0432.CCR-19-0463. [Epub ahead of print]

PMID:
31515457
2.

Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.

PMID:
28279941
3.

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.

de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2.

PMID:
28155054
4.

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS.

Breast Cancer Res Treat. 2016 Jul;158(2):361-71. doi: 10.1007/s10549-016-3878-9. Epub 2016 Jun 29. Erratum in: Breast Cancer Res Treat. 2016 Sep;159(2):393.

PMID:
27357813
5.

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).

Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching PA, Tesch H, Eggemann H, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Loibl S; GBG and the AGO-B Study Group.

J Clin Oncol. 2018 May 1;36(13):1308-1316. doi: 10.1200/JCO.2017.75.9175. Epub 2018 Mar 15.

PMID:
29543566
6.

Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?

Wong FY, Yip CS, Chua ET.

World J Surg. 2012 Feb;36(2):287-94. doi: 10.1007/s00268-011-1353-7.

PMID:
22105650
7.

One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.

Inno A, Barni S, Ghidini A, Zaniboni A, Petrelli F.

Breast Cancer Res Treat. 2019 Jan;173(2):247-254. doi: 10.1007/s10549-018-5001-x. Epub 2018 Oct 13.

PMID:
30317424
8.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N.

J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.

9.

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients.

Qin T, Yuan Z, Peng R, Bai B, Shi Y, Teng X, Liu D, Wang S.

Onco Targets Ther. 2013 Apr 9;6:341-7. doi: 10.2147/OTT.S40851. Print 2013.

10.

HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.

Stocker A, Hilbers ML, Gauthier C, Grogg J, Kullak-Ublick GA, Seifert B, Varga Z, Trojan A.

PLoS One. 2016 Jul 27;11(7):e0159176. doi: 10.1371/journal.pone.0159176. eCollection 2016.

11.

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.

Hayashi N, Niikura N, Yamauchi H, Nakamura S, Ueno NT.

Breast Cancer Res Treat. 2013 Jan;137(2):523-31. doi: 10.1007/s10549-012-2336-6. Epub 2012 Nov 27.

12.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2.

13.

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.

Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M.

J Clin Oncol. 2014 Mar 10;32(8):735-44. doi: 10.1200/JCO.2013.49.7693. Epub 2014 Jan 27.

14.

Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.

Kolben T, Harbeck N, Wuerstlein R, Schubert-Fritschle G, Bauerfeind I, Schrodi S, Engel J.

Breast. 2015 Feb;24(1):24-31. doi: 10.1016/j.breast.2014.10.007. Epub 2014 Nov 8.

PMID:
25543874
15.

Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).

von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer JU, Costa SD, Jackisch C, Paepke S, Schneeweiss A, Kümmel S, Denkert C, Mehta K, Loibl S, Untch M.

Ann Oncol. 2014 Jan;25(1):81-9. doi: 10.1093/annonc/mdt410. Epub 2013 Nov 21.

PMID:
24273046
16.

Prognostic Role of HER2 Status and Adjuvant Trastuzumab Treatment in Lymph Node-Negative Breast Cancer Patients - a Retrospective Single Center Analysis.

Fokter Dovnik N, Dovnik A, Čas Sikošek N, Ravnik M, Arko D, Takač I.

Breast Care (Basel). 2016 Dec;11(6):406-410. doi: 10.1159/000454690. Epub 2016 Dec 9.

17.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD.

J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22.

18.

Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.

Sánchez-Muñoz A, Navarro-Perez V, Plata-Fernández Y, Santonja A, Moreno I, Ribelles N, Alba E.

Clin Breast Cancer. 2015 Oct;15(5):343-7. doi: 10.1016/j.clbc.2015.01.005. Epub 2015 Jan 21.

PMID:
25752727
19.

Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.

Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C.

Clin Breast Cancer. 2018 Aug;18(4):e687-e694. doi: 10.1016/j.clbc.2017.11.012. Epub 2017 Nov 23.

PMID:
29275864
20.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.

Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.

PMID:
24657003

Supplemental Content

Support Center